2. Veeva Systems Inc. (NYSE:VEEV)
In the ecosystem of AI in healthcare and life sciences, Veeva Systems Inc. occupies a unique and highly strategic position. Rather than focusing on a single application, Veeva is building what can best be described as the operating system for the pharmaceutical industry—one that is increasingly powered by artificial intelligence.
What sets Veeva apart is its deep integration into the workflows of major pharmaceutical companies. As demand grows for AI-enhanced platforms that can streamline everything from clinical trials to regulatory compliance, Veeva is becoming the preferred partner for large-scale drug developers. This is not speculation; industry feedback suggests that even companies currently using competing platforms are considering switching to Veeva due to its AI capabilities.
The company’s recent acquisition of Ostro further strengthens its position. By integrating AI-powered patient engagement tools into its ecosystem, Veeva is expanding beyond internal operations into direct patient interaction, creating a more holistic AI healthcare platform. This move reflects a broader trend in the industry, where the lines between software, data, and patient care are increasingly blurred.
Strong financial performance reinforces this strategic positioning. With revenue growing 16% year-over-year and earnings surpassing expectations, Veeva continues to demonstrate that AI-driven enterprise healthcare solutions can deliver consistent and scalable growth. For investors seeking exposure to top AI healthcare infrastructure companies, Veeva stands as one of the most compelling long-term plays.
Click next to see the following stock...
